Retatrutide vs Tirzepatide — Triple Agonist vs Dual Agonist Comparison
Retatrutide and Tirzepatide are both injectable peptides for weight loss and metabolic health, but they work on different numbers of receptors. Tirzepatide is FDA-approved and activates two receptors (GLP-1 and GIP). Retatrutide is investigational and activates three (GLP-1, GIP, and glucagon), which appears to drive even greater weight loss in trials. Here's how they compare.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 + GIP + Glucagon (triple agonist) | GLP-1 + GIP (dual agonist) |
| Brand Names | None yet — investigational | Mounjaro (diabetes), Zepbound (obesity) |
| FDA Approval | Phase 3 trials (TRIUMPH program); approval expected 2027–2028 | Diabetes: 2022. Obesity (Zepbound): 2023 |
| Average Weight Loss | ~28.7% at 12mg over 68 weeks (TRIUMPH-4) | ~22.5% at 15mg over 72 weeks (SURMOUNT-1) |
| Blood Sugar Control | Reduces HbA1c ~2.0% (TRANSCEND-T2D-1, 12mg, 40wk) | Reduces HbA1c ~2–2.5% |
| Dosing | Once weekly injection. Titrates 2 → 4 → 6 → 9 → 12 mg over 16+ weeks | Once weekly injection. Titrates 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over 20+ weeks |
| GI Side Effects | Nausea, vomiting, diarrhea — common, dose-dependent | Similar profile — possibly slightly milder at high doses |
| Unique Side Effects | Dysesthesia (skin tingling/burning) ~21% at 12mg — not seen with Tirzepatide | None unique to this comparison |
| Heart Rate | Increase of 5–10 bpm peaking around week 24 | Mild increase in some users |
| Cardiovascular Data | TRIUMPH-3 CVOT pending (results expected 2027+) | SURPASS-CVOT ongoing |
| Availability | Research-grade only — clinical trials and research peptide vendors | Prescription only (insurance/cash) |
| Key Trial | TRIUMPH program Phase 3 | SURMOUNT-1, SURPASS-2 |
Choose Retatrutide if:
You're researching the highest-efficacy weight loss data available, can tolerate the dysesthesia risk, and don't need an FDA-approved or insurance-covered option. Best for research settings.
Choose Tirzepatide if:
You want an FDA-approved option backed by years of clinical use, prescription access, and slightly milder dysesthesia profile. Best when prescription path matters.
Consider the bigger picture:
For users tracking the GLP class as a whole, see the Semaglutide vs Tirzepatide vs Retatrutide 3-way comparison.
Dosing
Both are once-weekly subcutaneous injections titrated slowly upward to limit gastrointestinal side effects. These are the trial/label escalation schedules, provided for research context — retatrutide is research-use-only and neither should be dosed without medical oversight.
- Retatrutide: once weekly, titrating 2 → 4 → 6 → 9 → 12 mg over roughly 16+ weeks (12 mg is the top trial dose).
- Tirzepatide: once weekly, titrating 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg over roughly 20+ weeks (15 mg is the top label dose).
Side Effects
The two share a gastrointestinal profile; the clearest difference is retatrutide's dysesthesia signal.
- Shared (both): dose-dependent nausea, vomiting, and diarrhea — usually worst during dose escalation.
- Retatrutide-specific: dysesthesia (skin tingling or burning) in ~21% at 12 mg — not seen with tirzepatide — plus a heart-rate increase of ~5–10 bpm.
- Tirzepatide: GI profile broadly similar, possibly slightly milder at high doses; long-term safety established across years of clinical use.
- Note: retatrutide's longer-term safety is still being characterized in Phase 3 (cardiovascular outcome data pending).
Bottom Line
Retatrutide produces the largest average weight loss seen in any obesity drug, but it's still investigational. Tirzepatide has FDA approval, prescription access, and an established safety record. The dysesthesia signal in retatrutide trials (~21% at 12mg) is the most notable difference in side effect profiles.
FAQ
Is retatrutide stronger than tirzepatide?
In trials, retatrutide has produced greater average weight loss. As a triple agonist (GLP-1 + GIP + glucagon), at its 12 mg dose it reached ~24.2% average weight loss over 48 weeks in Phase 2 and ~28.7% over 68 weeks in the Phase 3 TRIUMPH-4 trial, with the weight-loss curve still declining. Tirzepatide, a dual agonist (GLP-1 + GIP), reached ~22.5% over 72 weeks in SURMOUNT-1. So retatrutide shows higher efficacy in trials — but it is still investigational, whereas tirzepatide is FDA-approved and available now.
Is retatrutide FDA-approved?
No. Retatrutide is still investigational and in Phase 3 trials (the TRIUMPH program); it is not FDA-approved and is not commercially available — research-grade material only. Tirzepatide, by contrast, is FDA-approved: for type 2 diabetes (Mounjaro, 2022) and for obesity (Zepbound, 2023). Retatrutide approval is expected around 2027–2028 based on current trial timelines.
Can you switch from tirzepatide to retatrutide?
That is a prescriber-led medical decision, and for now it is largely hypothetical outside a clinical trial, because retatrutide is not commercially available. Both are once-weekly injectables that share GLP-1 and GIP activity (retatrutide adds a third, glucagon, receptor), so the classes are related — but there is no established cross-titration protocol, and any transition should be managed by a physician. Retatrutide is currently accessible only through clinical trials or as a research-use-only compound.
How much more weight loss does retatrutide show?
A few percentage points of body weight in the trial data. Retatrutide reached ~24.2% at 48 weeks (Phase 2) and ~28.7% at 68 weeks (TRIUMPH-4), versus ~22.5% for tirzepatide over 72 weeks (SURMOUNT-1). The gap partly reflects retatrutide's third (glucagon) receptor and longer-running trials whose weight-loss curves had not yet plateaued. These figures come from different trials and durations, so they are not a direct head-to-head comparison.
What are the main side effects of each?
Both cause dose-dependent gastrointestinal effects — nausea, vomiting, and diarrhea — usually worst during dose escalation. Retatrutide additionally shows a distinctive dysesthesia signal (skin tingling or burning) reported in roughly 21% of participants at the 12 mg dose, which is not seen with tirzepatide, plus a heart-rate increase of about 5–10 bpm. Tirzepatide's GI profile is broadly similar and possibly slightly milder at high doses. Retatrutide's longer-term safety is still being characterized in Phase 3.
Related comparisons
For educational and research purposes only. Not medical advice.
Have a question about Retatrutide vs Tirzepatide — Triple Agonist vs Dual Agonist Comparison? Send us an email →